Data Sheet 6_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Data Sheet 5_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Image 2_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

“…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. …”

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 3_HIV risk and influence factors among MSM who had sought sexual partners in core venues: a continuous sentinel surveillance in 2010–2022.png by Zijie Yang (6330086)

“…Notably, 17 core venues were identified out of the 68 reported MSM venues, with 1,486 MSM who had sought sexual partners in core venues. These MSM had significantly higher risk of HIV and were more likely to take HIV testing and receive intervention services. …”

Experiences communicating in noise with aphasia (Harmon et al., 2024) by Tyson G. Harmon (11450904)

“…</p><p dir="ltr"><b>Results: </b>Quantitative findings showed that people with aphasia reported significantly greater perceived effort and stress than controls. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Our updated analysis confirmed at PC therapy significantly improves OS (hazard ratio [HR]: 0.73 [0.69, 0.77], P < 0.00001), PFS (HR: 0.56 [0.52, 0.60], P < 0.00001), duration of response (DOR, HR: 0.50 [0.45, 0.54], P < 0.00001) and objective response rate (ORR, risk ratio [RR]: 1.59 [1.51, 1.67], P < 0.00001) compared to chemotherapy alone. …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Data Sheet 1_Adherence to a “MediterrAsian” diet is associated with weight loss-independent improvements in liver fat and lipid profile, but not glucoregulation or inflammation: se... by Yu Chung Chooi (18968382)

“…</p>Results<p>Body weight, total body fat, visceral and subcutaneous adipose tissues, and liver fat decreased significantly after the intervention, in tandem with improvements in markers of glucose and lipid metabolism and inflammation. …”